Prajwala Nagaraju and Nandini Manoli
Breast cancer has ranked number one cancer among Indian females with age adjusted rate as high as 25.8 per 100,000 women and mortality 12.7 per 100,000
women. Diagnosis of Breast lesion has leaped rapidly from FNAC to molecular methods .In some institutes, the best possible cost effective diagnosis is given,
whereas in others, molecular studies are done to provide the diagnosis . Immunohistochemical markers like ER, PR , Her2 neu, growth factor receptor -2, Ki- 67,
progesterone receptor and p53 are used in breast cancer. Most commonly used among them are ER, PR and Her2 neu , which have array of use in subtyping ,
treatment and determining prognosis.
ER(Estrogen receptor) serves dual roles in breast cancer by predicting favorable disease outcome and by facilitating tumor progression. Up-regulation of ER and/
or the selection of specific ER mutations are early events important for facilitating tumor progression.
Along with estrogen receptor (ER), HER-2 is an important gene for molecular targeting treatment . As compared with HER2-negative tumors, HER2-positive
breast cancer is aggressive subtype that demonstrates unique epidemiological, clinical, and prognostic differences with poor response to standard chemotherapy
regimens. The HER2 gene amplification in the breast cancer is closely related to tumor-cell multiplication ,invasion ,high mitotic count and positive-lymph node
metastases, resulting in focal progression and distant metastases leading to adverse survival outcome.
Our study aims at correlating Her2 Neu with ER status, mitotic count , lymph node status, lymphovascular invasion.
Share this article
Journal of Oncology Translational Research received 93 citations as per Google Scholar report
